Spinomix grabs Pietro Scalfaro as new CEO

Spinomix grabs Pietro Scalfaro as new CEO

Spinomix formally announced the appointment of Pietro Scalfaro as Chief Executive Officer. This announcement builds on the momentum initiated earlier this year when Spinomix closed of a Series A equity investment of $3 million (USD).

Pietro has nearly 25 years of combined clinical practice and business acumen. Over the course of his 10-year tenure at Debiopharm, where he served as Chief Project Officer, Pietro led several successful drug development programs and implemented the Portfolio and Personalized Medicine Strategy – a streamlined approach covering all relevant pharmaceutical functions across 15 programs at different stages of development. Pietro has significant experience leading private equity investments for start-up molecular diagnostic companies focused on personalized medicine and has served on the boards of Agendia, Biocartis, Diagnoplex SA, and Immunexpress. Pietro holds an M.D. in gastroenterology and is a specialist in intensive care pediatrics. He received an executive Masters of Business Administration (MBA) in corporate finance from the University of Lausanne.

www.spinomix.com

 

Leave a reply